The Annual Meeting of the American Association of Immunologists
Autoantibodies are increasingly being studied as a source of disease insight. But how do you interpret them at scale?
If you’re attending IMMUNOLOGY2026™ in Boston from April 15–19, visit the CDI Labs team at booth #1015 to discuss this question. CDI Labs supports proteome-wide autoantibody profiling and biomarker discovery using high-content platforms, including:
• HuProt™ Human Proteome Microarrays for screening across more than 21,000 full-length human proteins • HuScan® PhIP-Seq for epitope-level autoantibody profiling • VirScan® PhIP-Seq for analysing antibody responses to viral exposure • VirScan® Exposome PhIP-Seq for analysing antibody responses to viral, bacterial, fungal and allergens exposure
These approaches allow researchers to examine antibody responses across both the human proteome and external exposures, supporting studies in immune-mediated disease and biomarker discovery.